Literature DB >> 33196415

Allogeneic cord blood red blood cells: assessing cord blood unit fractionation and validation.

Maria Bianchi1, Nicoletta Orlando2, Ombretta Barbagallo1, Sabrina Sparnacci1, Caterina Giovanna Valentini1, Brigida Carducci3, Luciana Teofili1,2.   

Abstract

BACKGROUND: For neonates and preterm infants, in whom a transfusion dose is low, the use of red blood cells (RBC) from cord blood appears to be feasible. Standardisation of fractionation and identification and assessment of quality control parameters for such RBC are still lacking.
MATERIALS AND METHODS: We describe the process used to obtain RBC from cord blood for transfusion purposes, including quality controls to evaluate fractionation performance and the effects of storage. The cord RBC, to which SAG-M was added, were sampled on the day of fractionation, and 7 and 14 days (end of storage) later in order to measure the complete blood count, biochemical parameters and residual white blood cells. We also assessed microbial contamination.
RESULTS: Data relative to 279 cord blood units were evaluated. The median gestational age at collection was 40 weeks (interquartile range [IQR] 39.1-40.7) and the median volume was 90 mL (IQR 81-103). Units were subjected to automated fractionation with Compomat, and packed RBC were suspended in SAG-M solution. The median volume of the SAG-M-suspended units was 31 mL (IQR 24.0-38.1) and the median haematocrit was 54.2% (IQR 49.4-59.5). The median volume after leukoreduction was 22 mL (IQR 17-28), with the volume decrease being similar in units leukoreduced before (n=75) or after (n=204) storage. The haematocrit of leukoreduced units was higher than that of buffy coat-depleted units. Storage at 2-6 °C for 14 days was accompanied by an increase of potassium levels and percentage of haemolysis. Microbial cultures were positive for 2.9% of the collected units. DISCUSSION: Fractionation of whole cord blood can provide RBC concentrates with similar baseline characteristics as units from adults. The transfusion dose and quality of the units appear safe and suitable for clinical use in neonates, with a satisfactory haematocrit and residual white blood cell content, despite a very variable collection volume.

Entities:  

Mesh:

Year:  2020        PMID: 33196415      PMCID: PMC8486608          DOI: 10.2450/2020.0138-20

Source DB:  PubMed          Journal:  Blood Transfus        ISSN: 1723-2007            Impact factor:   3.443


  45 in total

1.  Can cord blood be used for autologous transfusion in preterm neonates?

Authors:  D V Surbek; R Glanzmann; H P Senn; I Hoesli; W Holzgreve
Journal:  Eur J Pediatr       Date:  2000-10       Impact factor: 3.183

2.  Processing cord blood from premature infants into autologous red-blood-cell products for transfusion.

Authors:  C M Khodabux; J M van Beckhoven; J G M Scharenberg; F El Barjiji; M C Slot; A Brand
Journal:  Vox Sang       Date:  2010-11-23       Impact factor: 2.144

3.  The efficacy of autologous cord-blood transfusions in neonatal surgical patients.

Authors:  Tomoaki Taguchi; Sachiyo Suita; Masatoshi Nakamura; Takeshi Yamanouchi; Keiko Ogita; Shohei Taguchi; Toru Uesugi; Hitoo Nakano; Shoichi Inaba
Journal:  J Pediatr Surg       Date:  2003-04       Impact factor: 2.545

4.  Effects of red-cell storage duration on patients undergoing cardiac surgery.

Authors:  Marie E Steiner; Paul M Ness; Susan F Assmann; Darrell J Triulzi; Steven R Sloan; Meghan Delaney; Suzanne Granger; Elliott Bennett-Guerrero; Morris A Blajchman; Vincent Scavo; Jeffrey L Carson; Jerrold H Levy; Glenn Whitman; Pamela D'Andrea; Shelley Pulkrabek; Thomas L Ortel; Larissa Bornikova; Thomas Raife; Kathleen E Puca; Richard M Kaufman; Gregory A Nuttall; Pampee P Young; Samuel Youssef; Richard Engelman; Philip E Greilich; Ronald Miles; Cassandra D Josephson; Arthur Bracey; Rhonda Cooke; Jeffrey McCullough; Robert Hunsaker; Lynne Uhl; Janice G McFarland; Yara Park; Melissa M Cushing; Charles T Klodell; Ravindra Karanam; Pamela R Roberts; Cornelius Dyke; Eldad A Hod; Christopher P Stowell
Journal:  N Engl J Med       Date:  2015-04-09       Impact factor: 91.245

5.  Autologous cord blood transfusion in preterm infants - could its humoral effect be the kez to control prematurity-related complications? A preliminary study.

Authors:  M Kotowski; Z Litwinska; P Klos; E Pius-Sadowska; E Zagrodnik-Ulan; P Ustianowski; J Rudnicki; B Machalinski
Journal:  J Physiol Pharmacol       Date:  2017-12       Impact factor: 3.011

6.  A preliminary report of 123 units of placental umbilical cord whole blood transfusion in HIV-positive patients with anemia and emaciation.

Authors:  N Bhattacharya
Journal:  Clin Exp Obstet Gynecol       Date:  2006       Impact factor: 0.146

7.  Placental umbilical cord whole blood transfusion to combat anemia in the background of tuberculosis and emaciation and its potential role as an immuno-adjuvant therapy for the under-resourced people of the world.

Authors:  N Bhattacharya
Journal:  Clin Exp Obstet Gynecol       Date:  2006       Impact factor: 0.146

8.  Quality and stability of red cells derived from gravity-separated placental blood with a hollow-fiber system.

Authors:  Thomas Brune; Sara Fill; Gerd Heim; Angelika Rabsilber; Kathrin Wohlfarth; Henk S P Garritsen
Journal:  Transfusion       Date:  2007-08-21       Impact factor: 3.157

9.  Placental umbilical cord blood transfusion in transfusion-dependent beta thalassemic patients: a preliminary communication.

Authors:  N Bhattacharya
Journal:  Clin Exp Obstet Gynecol       Date:  2005       Impact factor: 0.146

10.  Autologous umbilical cord blood transfusion.

Authors:  A Ballin; E Arbel; G Kenet; M Berar; D Kohelet; A Tanay; H Zakut; D Meytes
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1995-11       Impact factor: 5.747

View more
  1 in total

1.  Recycling Apparent Waste Into Biologicals: The Case of Umbilical Cord Blood in Italy and Spain.

Authors:  Paolo Rebulla; Sergio Querol; Simonetta Pupella; Daniele Prati; Joaquin Delgadillo; Vincenzo De Angelis
Journal:  Front Cell Dev Biol       Date:  2022-01-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.